SCHEMBL26773559

SCHEMBL26773559

O=c1oc2cc3[nH]nnc3cc2c2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 3/20 0.46
▸ RXFP1 Q9HBX9 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ PPARG P37231 2/20 0.46
▸ NCOA2 Q15596 2/20 0.46
▸ ALDH2 P05091 1/20 0.46
▸ NCOR2 Q9Y618 1/20 0.46
▸ KMT2A Q03164 2/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ BCHE P06276 4/20 0.39
▸ ACHE P22303 4/20 0.39
▸ MAOB P27338 1/20 0.38
▸ ELANE P08246 5/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26773446 0.83 PDE2A (0.57) NPSR1RXFP1LMNAKMT2AALDH1A1
SCHEMBL26773294 0.73 NPSR1 (0.46) NPSR1RXFP1LMNAPPARGNCOA2
SCHEMBL16925861 0.71 AHR (0.53) NPSR1RXFP1LMNAPPARGNCOA2
SCHEMBL26773449 0.71 F2 (0.54) NPSR1RXFP1LMNAPPARGNCOA2
SCHEMBL26773444 0.69 ESR2 (0.44) NPSR1RXFP1KMT2ANPC1SMN1; SMN2
SCHEMBL16925834 0.68 AHR (0.58) NPSR1RXFP1LMNAPPARGNCOA2
SCHEMBL26773290 0.68 NPSR1 (0.46) NPSR1RXFP1LMNAPPARGNCOA2
SCHEMBL15430828 0.67 AHR (0.57) ALDH1A1MAPTKDM4E
SCHEMBL29709713 0.65 KMT2A (0.62) NPSR1RXFP1LMNAPPARGNCOA2
SCHEMBL29416517 0.65 KMT2A (0.62) NPSR1RXFP1LMNAPPARGNCOA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820751-B2 Urolithin derivatives and methods of use thereof VANDRIA SA (CH) 2023-11-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11820751-B2 Urolithin derivatives and methods of use thereof NLN, UQCRC2, TUFM NPSR1 3213/4885RXFP1 3981/4885LMNA 675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback